Toutes les photos(1)

Key Documents

COO/COA

View All Documentation

Y0000370

Risperidone for system suitability

Name: Risperidone for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Risperidone, R 64,766

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₂₃H₂₇FN₄O₂

Numéro CAS:

106266-06-2

Poids moléculaire :

410.48

Numéro MDL:

MFCD00274576

Code UNSPSC :

41116107

ID de substance PubChem :

329830925

Nomenclature NACRES :

NA.24

Produits recommandés

Slide 1 of 10

1 of 10

USP

1604676

Risperidone Related Compounds Mixture

R1000600

Risperidone

Sigma-Aldrich

SML3059

Lacosamide

Y0001276

Risperidone impurity K

Supelco

PHR1631

Risperidone

USP

1151855

Curcumin

M1825000

Metoclopramide hydrochloride

I0750000

Isopropyl tetradecanoate

S0460000

Sertaconazole nitrate

BP1158

Risperidone impurity standard

Qualité

pharmaceutical primary standard

Famille d'API

risperidone

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1

InChI

1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

Clé InChI

RAPZEAPATHNIPO-UHFFFAOYSA-N

Informations sur le gène

human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Risperidone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

1604676

Y0001276

Risperidone impurity K, European Pharmacopoeia (EP) Reference Standard

1604756

PHR1631

Risperidone, Pharmaceutical Secondary Standard; Certified Reference Material

BP1137

Risperidone, British Pharmacopoeia (BP) Reference Standard

BP1158

Risperidone impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

GHS06

Mention d'avertissement

Danger

Mentions de danger

H301

Conseils de prudence

P301 + P330 + P331 + P310

Classification des risques

Acute Tox. 3 Oral

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Comparative study of the complex forming ability and enantioselectivity of cyclodextrin polymers by CE and 1H NMR.

Cécile Danel et al.

Carbohydrate polymers, 92(2), 2282-2292 (2013-02-13)

The interactions between nine drugs (baclofen, bupivacaine, chlorpheniramine, ketoconazole, paliperidone, promethazine, propranolol, risperidone and verapamil) and six cyclodextrins (α-CD, β-CD, γ-CD, HP-β-CD, HP-γ-CD and Me-β-CD) or six polymers of cyclodextrins (polyα-CD, polyβ-CD, polyγ-CD, polyHP-β-CD, polyHP-γ-CD and polyMe-β-CD) were studied by

Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients.

Vina M Goghari et al.

Schizophrenia research, 149(1-3), 149-155 (2013-07-09)

Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study

Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity.

Jérôme A J Becker et al.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(9), 2049-2060 (2014-03-13)

The etiology of Autism Spectrum Disorders (ASDs) remains largely unknown. Identifying vulnerability genes for autism represents a major challenge in the field and allows the development of animal models for translational research. Mice lacking the mu opioid receptor gene (Oprm1(-/-))

PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia.

Christian Spang Pedersen et al.

Behavioural brain research, 273, 63-72 (2014-07-30)

Schizophrenia is a severe psychiatric disorder characterized by three symptom domains, positive (hallucinations, obsession), negative (social withdrawal, apathy, self-neglect) and cognitive (impairment in attention, memory and executive function). Whereas current medication ameliorates positive symptomatology, negative symptoms as well as cognitive

Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.

Yvonne Freund-Levi et al.

Dementia and geriatric cognitive disorders, 38(3-4), 234-244 (2014-06-28)

To examine the effects of galantamine and risperidone on agitation in patients with dementia. A total of 100 patients with dementia and neuropsychiatric symptoms (mean age ± SD: 78.6 ± 7.5 years; 67% female) were included in this 12-week, randomized

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique